Skip to main content
Psychopharmacology Bulletin All Volumes & Issues VOL 37 No. 1 Psychotropic Drug-Induced Weight...
CASE HISTORIES

Psychotropic Drug-Induced Weight Gain Alleviated with Orlistat: A Case Series

Psychopharmacology Bulletin 37(1) :05-09 , 2003/01/15

Abstract

Weight gain is a common side effect associated with antidepressant, anxiolytic, and antipsychotic drug use. Obesity is a risk factor for several other disorders, including hypertension, diabetes, and coronary artery disease. To date, there have been few safe, well-tolerated, and effective pharmacological agents available to alleviate weight gain in general, and virtually no studies specific to psychiatric drug-induced weight gain. This case series looks at the use of orlistat, a reversible inhibitor of lipases approved by the US Food and Drug Administration for obesity management, naturalistically in 13 patients with weight gain secondary to psychotropic drug use. The results showed that orlistat, administered in three daily doses with meals, was safe, well-tolerated, and effective, resulting in an average weight loss of 3–5% during an acute treatment period of about three months. Psychopharmacology Bulletin. 2003;37(1):5-9.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Thomas L. Schwartz, MD, and Mark Beale, MD. Psychotropic Drug-Induced Weight Gain Alleviated with Orlistat: A Case Series. Psychopharmacology Bulletin. 2003/01/15; 37(1):05-09.